Glutathione: What It Is, Where to Get It Prescribed, and What It Costs

Glutathione is three amino acids joined together: glutamate, cysteine and glycine. Every nucleated cell synthesises it, and it sits inside cells at millimolar concentrations, the most abundant small thiol in the body. A 2013 review in Biochimica et Biophysica Acta describes the pathway: cysteine supply usually caps how much a cell can make.

Unlike most peptides on this site, glutathione does not bind a receptor. It is a working molecule, consumed and regenerated continuously, so the clinical question is not "what does it do" but "does giving more from outside change anything, and by which route."

The active form is reduced glutathione, GSH. When it neutralises a reactive species it becomes glutathione disulfide, GSSG, and glutathione reductase converts it back using NADPH. The GSH:GSSG ratio is a standard laboratory measure of oxidative stress and appears as an endpoint in several trials below. The compounded injection is the reduced form.

It is not a hormone, a growth factor or a stimulant. It is not a treatment for any diagnosed disease: the Parkinson's, liver and pigmentation trials are discussed here for what they say about the molecule, not as indications. And it is not "detox" in the marketing sense — the word has a precise meaning here, covered next.

The cysteine thiol donates an electron to peroxides and radicals and is oxidised in the process — what most people mean by "antioxidant." A 2009 review in Biological Chemistry lists low glutathione as a feature of many human diseases while noting it is usually a marker of oxidative stress rather than a proven cause.

This is where "detoxification" has real meaning. Glutathione peroxidases use GSH to reduce peroxides; glutathione S-transferases attach GSH to reactive drug metabolites and toxicants so they can be excreted. The familiar example is acetaminophen: overdose becomes dangerous when hepatic glutathione runs out, which is why the antidote is a glutathione precursor.

The pigmentation research rests on interaction with tyrosinase, the rate-limiting enzyme of melanin synthesis, and a shift from dark eumelanin toward lighter phaeomelanin. A 2016 review in the Indian Journal of Dermatology, Venereology and Leprology lays this out and is openly sceptical of how far marketing has outrun the evidence.

Lymphocyte function depends on intracellular glutathione, and the two oral trials below used natural killer cell cytotoxicity as a secondary endpoint. The proposed mechanism is repletion, not stimulation: depleted immune cells perform poorly and replete ones perform normally.

A 1992 paper in the European Journal of Clinical Pharmacology gave seven volunteers a single oral dose and found plasma glutathione did not rise. Longer trials complicated that. A 2015 randomised, double-blind, placebo-controlled trial in the European Journal of Nutrition gave 54 non-smoking adults 250 or 1,000 mg daily for six months: the high-dose group ended 30 to 35 percent above baseline in red cells, plasma and lymphocytes, natural killer cytotoxicity more than doubled versus placebo at three months, and levels returned to baseline after a one-month washout. A 2018 pilot in the European Journal of Clinical Nutrition reported similar rises with a liposomal form in 12 adults. Against that, a 2011 randomised trial in the Journal of Alternative and Complementary Medicine gave 40 adults 500 mg twice daily for four weeks and found no change. The honest reading: oral glutathione probably raises body stores over months, a single dose does not, and four weeks may be too short to show it.

Three small randomised trials exist, all in healthy volunteers. A 2012 study in the Journal of Dermatological Treatment gave 60 medical students 500 mg oral glutathione or placebo for four weeks; melanin index fell more than placebo at two of six sites. A 2017 study in Clinical, Cosmetic and Investigational Dermatology gave healthy women 250 mg reduced or oxidised glutathione or placebo for 12 weeks; melanin index tended lower in both active arms. A 2014 trial in the same journal tested a topical oxidised-glutathione lotion with a similar result. None ran longer than three months. The 2016 review states that intravenous glutathione for skin lightening has no controlled evidence. Pepti does not supply glutathione for skin lightening.

This is where the intravenous data lives. A 1996 open-label study in Progress in Neuro-Psychopharmacology and Biological Psychiatry gave nine patients with early untreated Parkinson's disease 600 mg intravenously twice daily for 30 days and reported a 42 percent fall in disability scores. The follow-up, a 2009 randomised, double-blind, placebo-controlled pilot in Movement Disorders, gave 21 patients 1,400 mg intravenously three times a week for four weeks: well tolerated, adverse events similar to placebo, and no significant difference in Unified Parkinson's Disease Rating Scale scores. A 2017 phase IIb trial in the Journal of Parkinson's Disease tested intranasal glutathione for three months in 45 patients; every arm improved, including placebo, and neither dose beat it.

A 1995 randomised, double-blind, placebo-controlled trial in the Journal of Clinical Oncology gave intravenous glutathione alongside cisplatin to patients with advanced gastric cancer and reported less peripheral neuropathy without loss of the chemotherapy's activity — a genuine controlled result, in a specific population receiving a specific neurotoxic drug.

A 2017 open-label, single-arm pilot in BMC Gastroenterology gave 34 patients with non-alcoholic fatty liver disease 300 mg oral glutathione daily for four months after a diet-and-exercise run-in. Alanine aminotransferase and triglycerides fell. With no control group the result cannot be separated from continued lifestyle change.

A 2023 randomised, placebo-controlled trial in the Journals of Gerontology gave 24 older adults glycine plus N-acetylcysteine or placebo for 16 weeks and reported correction of baseline glutathione deficiency, with lower oxidative stress markers and improved gait speed and grip strength. It is not a glutathione trial, but it is the strongest controlled evidence that restoring low glutathione changes physiology.

The precise position: glutathione has randomised controlled human trials by mouth, by vein, by nose and on the skin. There are no randomised controlled trials of subcutaneous glutathione, which is the route this product uses. The subcutaneous route rests on the pharmacology of the molecule, on tolerability shown in intravenous trials at far higher doses, and on prescribing experience.

A 1991 study in the European Journal of Clinical Investigation found high-dose intravenous glutathione rose sharply in plasma and cleared within minutes to an hour — a brief pulse, then delivery of its amino acids. Whether a small subcutaneous depot behaves the same way has not been measured. A prescriber who says subcutaneous glutathione "works like an IV" is extrapolating; so is one who says it does not.

• It does not establish that subcutaneous glutathione raises tissue glutathione; that has not been measured.
• It does not establish an effect on any disease. The controlled Parkinson's trials did not separate from placebo; the fatty liver work had no control; the cisplatin result applies to people receiving cisplatin.
• It does not establish an effect on skin tone by injection.
• It does not establish long-term safety of years of continuous injection.
• It does not establish efficacy for any condition as an FDA-approved treatment. Glutathione injection is not an FDA-approved drug product.

Most people notice nothing in the first several doses, and that is expected: glutathione has no stimulant, sedative or analgesic action. Mild injection-site soreness and occasional brief lightheadedness are what gets reported.

The oral trials that measured body stores found changes meaningful by one month and larger by three to six. If subcutaneous dosing raises stores at all, this is the window prescribers describe, and it is why a vial is sized at about four weeks. Anything reported in this period is a subjective report, not a measured endpoint.

The 2015 oral trial found levels back at baseline within a month of stopping. Prescribers describe glutathione as maintained while it is being given rather than something that resets a baseline.

Whole-blood glutathione and the GSH:GSSG ratio are measurable, and a physician who wants an objective marker can order them, though they are not routine. At-home blood testing covers hormone, metabolic and thyroid markers.

The directions are written in millilitres and insulin-syringe units because that is what you read off the barrel. 0.41 mL is 41 units on a U-100 syringe; the number is printed on your medication. A 0.41 mL draw is a small fraction of the gram-level intravenous doses in the Parkinson's trials, one reason those findings should not be assumed to transfer.

Subcutaneous means into the fat layer, not muscle and not a vein. Abdomen and thigh are the usual sites, rotated. Three times a week is the reviewed schedule; spacing is in your directions. Glutathione must never be injected into a vein.

12 doses at three times per week is four weeks, which is why refills run on a 28-day cycle. One vial per fill, always — not a stockpile. The 2,000 mg/10 mL strength is the same concentration in a larger vial.

Refrigerated, and it ships that way in insulated packaging with ice packs. Reduced glutathione oxidises on exposure to air, which is why the vial stays cold and capped and why beyond-use dating, printed on the label, runs from first puncture.

Related, not interchangeable. NAD+ is a coenzyme in hundreds of reactions, including the one that regenerates reduced glutathione; glutathione is the working antioxidant itself. NAD+ has the larger human trial base and is the one more prescribers reach for first on energy and recovery; glutathione is the more specific choice where oxidative burden is the reason for prescribing. They are frequently prescribed together.

The glutathione pigmentation trials are oral and topical; there is no controlled evidence for injected glutathione and skin tone. GHK-Cu is described around collagen and extracellular-matrix signalling rather than pigment, and if skin is the reason for the conversation, expect the physician to steer there or to the KLOW blend.

The oral evidence is the larger body of work, and the six-month trial shows oral supplementation can raise body stores. The case for injection is bypassing gut hydrolysis. Neither route has trial evidence for disease outcomes in a general population, and it is fair to ask your physician why injection is being recommended.